Welcome fellow bloggers. I’d love to read your thoughts on the topics below.

Vince Kuraitis:

Considering that private health plans seem to follow the lead of Medicare, what should CMS do to encourage innovation in disease management and remote patient monitoring? How effective are current CMS efforts in this area?

Derek Lowe:

The pharmaceutical industry boasts of being innovative, but does that claim hold up? After all, the industry trumpets the high and rising cost of developing drugs –which seems like an indicator of inefficiency and bloat. Few truly novel products are introduced, but there seems to be plenty of innovation in keeping generics off the market. The biggest companies with the highest research budgets still seem to license in more compounds than they discover themselves. So is the industry innovative and if so in what ways?

Emily DeVoto:

They say “necessity is the mother of invention.” How have budget-constrained, socialized health care systems managed to do more with less? In particular who’s done a good job at combining universal access, low cost, high quality and low waiting times? What lessons can we apply here?

Matthew Holt:

How do you think my proposal to institute price controls on off-patent biotech products (rather than finding a way to allow biogenerics) would impact innovation in the biotech industry?